ALCLS Cellectis SA

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)

PARIS, 01 déc. 2023 (GLOBE NEWSWIRE) --

Place de cotation : Euronext Growth

Code ISIN : FR0010425595

Date
Nombre total d’actions composant le capital socialNombre total de droits de vote
30/11/202377 751 20177 686 109



Pour de plus amples informations sur Cellectis, veuillez contacter :

Contact média :

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,

Contacts pour les relations avec les investisseurs :

Arthur Stril, Chief Business Officer, +1 (347) 809 5980,

Sandya von der Weid, Associate Director, LifeSci Advisors, 8

Pièce jointe



EN
01/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
 PRESS RELEASE

Cellectis Reports Full Year 2025 Financial Results and Provides a Busi...

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became eligible to transplantPivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) ongoing Best-in-class dual allogeneic CAR-T cell product targeting CD20 & CD22At current dose level, 88% ORR; 63% CR rate after 2+ prior lines of thera...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch